Christopher Hoimes, DO, joined the genitourinary oncology program at Duke Cancer Institute as Associate Professor of Medicine where he will serve as clinical investigator with a focus on GU cancers, experimental therapeutics, and early phase trials.
Hoimes has expertise in immunotherapy and biomedical engineering to advance cancer treatment and diagnostics. As director of GU malignancies at the Case Comprehensive Cancer Center at Seidman in Cleveland, OH, he built research teams that integrated radiologists, pathologists, and urologists with experts in biomedical engineering for novel imaging and drug development approaches. He has particular interest in clinical and preclinical applications of nanomaterials for drug delivery and imaging, antibody-drug conjugates, and immunoengineering. As a clinical investigator in Phase I and genitourinary malignancies, Hoimes serves as principal investigator of over 12 active Phase I, II and III trials. He served on the NCCN guidelines panel for bladder and penile cancers, serves on the SITC expert consensus panel for immunotherapy in bladder cancer, and was a founding member of the NCCN panel on cancer immunotherapy and related complications.
“We are excited to bring Chris’s tremendous knowledge and experience and collaborative approach in genitourinary cancers, and bladder cancer in particular, to our group,” said Daniel George, MD, director of genitourinary oncology at Duke Cancer Institute. “As an international expert in bladder cancer clinical research, Chris led early trials that supported the first indication of immune-conjugated therapy in bladder cancer. He is currently co-leading a Phase III trial of neoadjuvant chemotherapy immunotherapy in invasive bladder cancer, as well as studying several novel approaches to combining these strategies in unmet needs for patients with advanced bladder cancer. His research will increase the treatment options for patients at Duke and our region. Additionally, he is also well trained in cancer immunology and provides another interface for us with our DCI Center for Cancer Immunotherapy, as well as with our School of Engineering.”
Recognized as a global leader in genitourinary cancers, Hoimes was recently nominated for the Master Clinician Award (2019), awarded the ECOG Symposium Young Investigator Award, and received the Department of Defense Prostate Cancer Young Investigator Award. He presented abstracts at the European Society of Medical Oncology (ESMO) Annual Meetings, American Society of Clinical Oncology (ASCO) Annual Meetings and the American Urological Association (AUA) Annual Meetings. Additionally, he also authored multiple articles published in the Journal of Clinical Oncology, the Journal of Urology and the New England Journal of Medicine.
Hoimes is board certified in Medical Oncology and Internal Medicine and was previously on faculty at Case Western Reserve University and Yale University. He received his medical degree from New York College of Osteopathic Medicine and completed Internal Medicine Residency and Chief at Penn State University and fellowship in Medical Oncology at Yale University School of Medicine.
